On 9 July 2026, the European Commission adopted 20 delegated decisions spanning competition, energy, foreign policy, transport, research, health, and institutional matters, as recorded in the daily note of delegations (SEC(2026)190). The decisions were taken under delegated powers by the responsible Commissioners or the College.
In competition, DG COMP cleared four mergers under Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement: M.12458 (EWE HYDROGEN / VERBUND GREEN HYDROGEN / JV), M.12438 (ENAGÁS INTERNACIONAL / SNAM / TERÉGA), M.12460 (APOLLO FUNDS / FORVIA AUTOMOTIVE INTERIORS BUSINESS), and M.12450 (GA GROUP / TA / POWERGEM). These clearances allow the transactions to proceed without in-depth investigation, indicating no serious competition concerns.
On energy, DG ENER adopted four decisions on nuclear safeguards for Finland's Olkiluoto encapsulation and disposal facilities (MBA W0LE, W0LF), ensuring compliance with Euratom Treaty obligations. The decisions relate to material balance areas for spent fuel and waste.
Under foreign policy instruments (FPI), two financing decisions were taken: one supporting the Beninese Armed Forces under the European Peace Facility, and another promoting universalisation of the International Convention for the Suppression of Acts of Nuclear Terrorism (ICSANT). These decisions commit EU funds to security and non-proliferation objectives.
In transport, DG MOVE adopted three decisions on aviation security inspector authorisation and inspection notifications, part of the EU's ongoing oversight of aviation security standards.
For research, DG RTD took two Horizon Europe grant decisions, including reclassification of four EIC Accelerator projects to blended finance, shifting from grant-only to a mix of grant and equity.
comments on draft animal protection and veterinary acts; annual renewal of conditional marketing authorisations for Zemcelpro (veterinary), VITRAKVI, and AYVAKYT (oncology); and amendments for Febuxostat Viatris (gout) and Betmiga (overactive bladder). These renewals maintain market access for drugs that address unmet medical needs, subject to continued monitoring.
Institutional decisions by the Secretariat-General included a response to a confirmatory access-to-documents request (2025/0750) and approval of modifications to EEA Agreement annexes and protocols. The Legal Service approved powers in litigation before the Court of Justice and the General Court.
The merger clearances benefit the involved companies (EWE, Verbund, Enagás, Snam, Apollo, Forvia, GA Group) by allowing transactions to close, but may raise concerns for competitors about market concentration. The nuclear safeguards decisions impose compliance obligations on Finland's nuclear operator. The health renewals provide continued access for patients relying on these therapies, while the blended finance reclassification offers EIC beneficiaries more flexible funding but shifts risk from grants to repayable instruments. The Benin and ICSANT financing decisions commit EU taxpayers' funds to external security and non-proliferation, with limited direct impact on EU businesses.